Two different types of stalk-based universal influenza virus vaccine candidates — chimeric hemagglutinins and headless hemagglutinins — are currently in development.

The two types of vaccines might induce a different antibody profile.

Efficacy of anti-stalk antibodies in vivo is high despite low in vitro neutralization potential.

Long lasting immunity is important for universal influenza virus vaccines.